Fate Therapeutics (FATE) Capital Expenditures (2012 - 2026)

Fate Therapeutics has reported Capital Expenditures for 15 years, with the latest figure at $15000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 97.71% year-over-year to $15000.0; the trailing twelve-month figure through Mar 2026 stood at -$640000.0 (down 181.95% YoY), and the FY2024 full-year result was $140000.0, changed N/A from the prior year.
• Capital Expenditures for Q1 2026 stood at $15000.0, up from -$4.8 million in the prior quarter.
• The five-year high for Capital Expenditures was $16.8 million in Q2 2022, with the low at -$18.2 million in Q3 2022.
• Historically, Capital Expenditures has averaged $71176.5 across 5 years, with a median of $124000.0 in 2024.
• The largest YoY upside for Capital Expenditures was 4578.57% in 2025 against a maximum downside of 3939.52% in 2025.
• Fate Therapeutics' Capital Expenditures stood at -$933000.0 in 2022, then tumbled by 540.09% to -$6.0 million in 2023, then soared by 102.08% to $124000.0 in 2024, then plunged by 3939.52% to -$4.8 million in 2025, then surged by 100.32% to $15000.0 in 2026.
• The last three Capital Expenditures figures came in at $15000.0 (Q1 2026), -$4.8 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.